Nutra Pharma Corp. Reaches Settlement with SEC
CORAL SPRINGS, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC: NPHC), ("Nutra Pharma" or the "Company") reached a settlement with the U.S. Securities and Exchange Commission ...
Model output · Signal date 2026-11-06
Nutra Pharma Corp (NPHC) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 5150 stocks scored
Rank correlation · 90D
-18.0%
Spearman, 357 dates
Market Cap
$720K
small-cap · #27 of 28 peers
Summary
Nutra Pharma Corp (NPHC) stock forecast summary
Our AI scores Nutra Pharma Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Nutra Pharma Corp is a small-cap company with a market capitalization of $720K. It ranks number 27 by market capitalization among the 28 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast. Its Net Margin of 226.6% is the highest of the 19 peers that report one. Its Current Ratio of 0.02x is the lowest of the 25 peers that report one.
For NPHC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -18.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -21.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, NPHC included.
Price
NPHC price chart and AI forecast
Cross-section · 2026-11-06
How NPHC ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Nutra Pharma Corp (NPHC) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric.
Valuation & Market
| Metric | NPHC | Rank |
|---|---|---|
| Market Cap | $720K | 27/28 |
| EPS | $0.00 | – |
Profitability & Margins
| Metric | NPHC | Rank |
|---|---|---|
| ROA | 37.8% | 1/21 |
| ROIC | 6.0% | 4/18 |
| Operating Margin | -1219.7% | 22/23 |
| Net Margin | 226.6% | 1/19 |
| EBT Margin | 4323.5% | 1/23 |
Financial Health
| Metric | NPHC | Rank |
|---|---|---|
| Current Ratio | 0.02x | 25/25 |
| Quick Ratio | 0.02x | 23/23 |
| Interest Coverage | -63.2x | 20/21 |
| Working Capital | -$21M | 25/25 |
Cash Flow
| Metric | NPHC | Rank |
|---|---|---|
| Operating Cash Flow | -$1M | 17/27 |
Operational Efficiency
| Metric | NPHC | Rank |
|---|---|---|
| Inventory Turnover | 6.2x | 3/19 |
| Days Inventory | 59 days | 16/18 |
| Payables Period | 2232 days | 1/17 |
Income Statement
| Metric | NPHC | Rank |
|---|---|---|
| Operating Income | -$1M | 11/26 |
| Net Income | $240K | 3/21 |
| SG&A Expense | $2M | 16/16 |
| Cost of Goods Sold | $150K | 19/22 |
Dividend & Shareholder Information
| Metric | NPHC | Rank |
|---|---|---|
| Shares Outstanding | 7160M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $460K | |
| Inventory | $20K | |
| Total Liabilities | $22M | |
| Short-term Debt | $21M |
Quarterly Financial Reports
NPHC quarterly financials and insider trading
Industry Peers · Medicinal Chemicals & Botanical Products
Nutra Pharma Corp (NPHC) industry peers
Companies classified under the same SEC industry code as Nutra Pharma Corp (Medicinal Chemicals & Botanical Products): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| NPHC Nutra Pharma Corp | $720K | |
| DFTX Definium Therapeutics, Inc. | $4.47B | |
| TRLV Trulieve Cannabis Corp. | $1.97B | |
| CRON Cronos Group Inc. | $1.33B | |
| TLRY Tilray Brands, Inc. | $432M | |
| SNDL Sndl Inc. | $355M | |
| ACB Aurora Cannabis Inc | $332M | |
| CGC Canopy Growth Corp | $276M | |
| USNA Usana Health Sciences Inc | $256M | |
| GLAS Glass House Brands Inc. | $196M | |
| MDWD Mediwound Ltd. | $171M | |
| NAGE Niagen Bioscience, Inc. | $164M | |
| AAWH Ascend Wellness Holdings, Inc. | $75M | |
| FTLF Fitlife Brands, Inc. | $75M | |
| CHUC Charlie's Holdings, Inc. | $31M | |
| BTMD Biote Corp. | $30M | |
| MRMD Marimed Inc. | $26M | |
| HYEX Healthy Extracts Inc. | $21M | |
| MTEX Mannatech Inc | $16M | |
| ADIA Adia Med, Inc. | $9M | |
| GLUC Glucose Health, Inc. | $9M | |
| BON Bon Natural Life Ltd | $7M | |
| NAII Natural Alternatives International Inc | $7M | |
| PLSH Panacea Life Sciences Holdings, Inc. | $6M | |
| AIBT Aibotics, Inc. | $3M | |
| CYAN Cyanotech Corp | $3M | |
| IMCC Im Cannabis Corp. | $980K | |
| MEHA Functional Brands Inc. | $140K | |
| NTRR Neutra Corp. | N/A | |
| SNYRQ Synergy Chc Corp. | N/A |
Where NPHC sits on the market map
Life Sciences · Medicinal Chemicals & Botanical Products
News
Nutra Pharma Corp (NPHC) stock news
Nutra Pharma Corp. and Nyloxin To Begin Airing Television Commercials
Nutra Pharma Corp. (OTCPINK:NPHC - News) saw its share volume skyrocket on June 12th with 40,578,885 shares exchanging hands, 43 times higher than its three month daily average volume of 945,114 ...
Nutra Pharma Corp. (NPHC) Kicks-Off First Radio Test To Promote Cobra Venom Pain Reliever
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. Nutra Pharma, a biotech company developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus ...
FAQ
Nutra Pharma Corp (NPHC) stock forecast FAQ
What is the Nutra Pharma Corp (NPHC) stock forecast?
Our AI scores Nutra Pharma Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Nutra Pharma Corp stock predictions?
For NPHC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -18.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -21.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Nutra Pharma Corp forecasts updated?
Nutra Pharma Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Nutra Pharma Corp's industry peers?
30 issuers in our coverage, NPHC included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Aurora Cannabis Inc (ACB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.